Atara Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Atara Biotherapeutics, Inc. (ATRA) on May 23, 2019. The filing reports significant changes in corporate leadership, specifically the appointment of a new President and Chief Executive Officer (CEO) and the departure of the incumbent CEO and a senior research executive.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements and personnel changes.
Material Changes
- Appointment of New CEO: Pascal Touchon was appointed President, CEO, and Board member, effective June 24, 2019.
- Departure of Incumbent CEO: Isaac Ciechanover stepped down as President, CEO, and Board member effective May 28, 2019. He will serve as a special advisor until June 21, 2019.
- Resignation of R&D Head: Dr. Dietmar Berger, Global Head of Research and Development, resigned effective May 31, 2019.
Compensation and Management Commentary
Dr. Touchon's employment agreement includes the following compensation terms:
- Base Salary: $615,000 annually.
- Bonus Target: 65% of base salary, contingent on corporate goals.
- Equity Awards: A sign-on restricted stock unit (RSU) award valued at $640,000, an option to purchase 225,000 shares of common stock, and an additional 112,500 RSUs.
- Benefits: Relocation assistance, immigration support, and tax make-whole provisions.
Management stated that Dr. Ciechanover's departure was not the result of any disagreement with the Company regarding operations, policies, or practices.
Investor Verification Checklist
- Verify the exact start date of Dr. Touchon's employment (expected June 24, 2019) and the transition plan with Dr. Ciechanover.
- Review the full Executive Employment Agreement (Exhibit 10.1) for specific performance metrics tied to the bonus target.
- Assess the impact of Dr. Berger's resignation on the Company's research and development pipeline.
- Confirm the vesting schedules and terms for the equity awards granted to Dr. Touchon.